Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
← catalyst calendarNCT07750886 · readout ≤ 2,081 d
Sponsored by Natera, Inc. (industry) · NTRA — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-27 | estimated | When the study began enrolling |
| Primary completion | Apr 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Hodgkin Lymphoma
- T-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- High-Grade B-Cell Lymphoma
- Primary Mediastinal B-Cell Lymphoma
- Peripheral T-Cell Lymphoma
- Transformed Follicular Lymphoma
- Follicular Lymphoma Grade 3B
- Follicular Lymphoma
- Anaplastic Large Cell Lymphoma
Primary outcome
what the primary-completion date above is the date OFPrimary Outcome - Blood and Residual Tissue Specimen Collection from 160 Completed Participants for Blood-Based Cancer Monitoring and Detection and Cancer Assay Development.
measured 3 Years
Permalink · NTRA's whole pipeline · Catalyst calendar · Every registered study · What changed